Article
Ralph M. Meyer, MD, Director of Clinical Trials Group, National Cancer Institute of Canada, Queen's University, offers a counterpoint to the thoughts of Richard T. Hoppe, MD, on the role and utility of radiation therapy in patients with early stage Hodgkin's lymphoma.
Ralph M. Meyer, MD, Director of Clinical Trials Group, National Cancer Institute of Canada, Queen's University, offers a counterpoint to the thoughts of Richard T. Hoppe, MD, on the role and utility of radiation therapy in patients with early stage Hodgkin's lymphoma. He compares the clinical outcomes associated with the use of radiation therapy and conventional treatment regimens.
This video was taken on Monday, December 10, at the American Society of Hematology's 54th Annual Meeting in Atlanta, GA.
The Importance of Examining and Preventing Atrial Fibrillation